La chaîne d'options affiche les données clés des options sur actions de Precision BioSciences à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Precision BioSciences..

Precision BioSciences (NASDAQ:DTIL) Stock, Chaîne d'Options

PRECISION BIOSCIENCES INC

Precision BioSciences

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Precision BioSciences, Inc. - Common Stock

Precision BioSciences Inc

Press Releases

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

iECURE to Present Initial OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at 6th International Symposium on UCDs and 15th International Congress of Inborn Errors of Metabolism

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

iECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual Meeting

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

DTIL

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

aTyr Pharma

Biomea Fusion

Clene

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Coya Therapeutics

Entera Bio

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

EXoZymes

InflaRx

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Metagenomi

OKYO Pharma

Ovid Therapeutics

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Pelthos Therapeutics

Quince Therapeutics

AVITA Medical

Sutro Biopharma

Shattuck Labs

Whitehawk Therapeutics, Inc. - Common Stock

Comments

Precision BioSciences

Precision BioSciences (DTIL) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL